NIO752 Antisense Oligonucleotide for PSP (NCT04539041)
Overview
Mermaid diagram (expand to render)
NIO752 (development code RG6100) is an antisense oligonucleotide (ASO) therapeutic developed through a collaboration between [Roche](https://www.roche.com) and [Ionis Pharmaceuticals](https://www.ionispharma.com) designed to reduce [tau protein](/proteins/tau) expression by targeting the [MAPT gene](/genes/mapt). This Phase 1 study specifically evaluated the drug in patients with Progressive Supranuclear Palsy (PSP), a 4R-tauopathy characterized by accumulation of abnormal tau in subcortical structures leading to progressive postural instability, supranuclear gaze palsy, and cognitive decline["@smith2023"].
The clinical development of NIO752 represents a gene-silencing approach that directly targets the root cause of tau pathology rather than attempting to clear tau after it has already aggregated. This mechanism differs fundamentally from antibody-based immunotherapy approaches and offers the potential for disease modification by preventing tau production at its source["@bittner2021"][@schneider2022].
Study Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04539041 |
| Status | Completed |
| Study Type | Interventional (Phase 1) |
| Intervention | NIO752 (tau ASO) |
| Conditions | Progressive Supranuclear Palsy (PSP) |
| Sponsor | Roche |
| Collaborator | Ionis Pharmaceuticals |
| Administration | Intrathecal (lumbar injection) |
| Duration | Multiple ascending dose cohorts |
Mechanism of Action
Molecular Target and Design
NIO752 is a gapmer-style antisense oligonucleotide designed to bind specifically to the messenger RNA (mRNA) transcribed from the [MAPT gene](/genes/mapt)[@tau2024][@bittner2021]. The MAPT gene encodes the tau protein, a microtubule-associated protein that plays essential roles in neuronal function under normal conditions but becomes pathological when it hyperphosphorylates and aggregates into neurofibrillary tangles.
The ASO employs a gapmer design, which features a central deoxynucleotide "gap" flanked by modified nucleotide "wings." This structure is specifically optimized to recruit RNase H1 upon binding to the target mRNA. RNase H1 is an enzyme that recognizes DNA-RNA hybrid structures and cleaves the RNA strand, leading to degradation of the target mRNA before it can be translated into protein[@krebs2023].
Key aspects of NIO752's molecular design include:
- Sequence specificity: The ASO sequence is designed to be specific for the MAPT mRNA, minimizing off-target effects on other genes
- Gapmer chemistry: The gapmer configuration with 2'-O-methoxyethyl (2'-MOE) modifications provides enhanced nuclease resistance and optimal RNase H1 recruitment
- Length optimization: The oligonucleotide length is optimized for efficient hybridization to the target sequence while maintaining specificity
Once NIO752 binds to its complementary sequence on the MAPT mRNA, it forms a DNA-RNA hybrid duplex. RNase H1 specifically recognizes this hybrid structure and cleaves the RNA strand at multiple sites within the DNA-RNA heteroduplex[@krebs2023]. This cleavage leads to the destruction of the mRNA message, preventing it from being translated into tau protein in the ribosome.
The RNase H1 mechanism offers several advantages for tau reduction:
Catalytic activity: A single ASO molecule can guide the degradation of multiple mRNA molecules, as RNase H1 cleaves the RNA at multiple sites, leading to complete mRNA destruction
Allele-nonspecific targeting: Unlike allele-specific approaches, this mechanism reduces all tau isoforms regardless of underlying genetic mutations
Sustained effect: The reduction in mRNA leads to decreased tau protein production that persists until new mRNA is synthesized, providing durable target engagementThe MAPT gene produces six alternative splicing isoforms in the adult human brain through different combinations of exons 2, 3, and 10. These isoforms are categorized as 3R (three repeat) and 4R (four repeat) tau, depending on whether they contain three or four microtubule-binding repeats. PSP is classified as a 4R-tauopathy, meaning that the 4R isoform predominates in the pathological inclusions[@mapt2024].
NIO752 targets all tau isoforms because it binds to a region of the mRNA that is common to all splice variants. This comprehensive targeting ensures reduction of total tau burden regardless of which isoform is predominating in the disease context[@tau2024]. In PSP specifically, reducing 4R tau production addresses the primary pathological driver while also lowering total tau burden.
Clinical Development Rationale
Why PSP as a Target Indication
PSP represents an ideal indication for tau-reduction therapy for several reasons:
Tau-centric pathology: PSP is driven primarily by tau aggregation, making tau reduction a direct disease-modifying approach
Genetic evidence: Mutations in MAPT cause familial frontotemporal dementia, demonstrating that tau dysregulation is sufficient to cause neurodegeneration
Limited treatment options: No disease-modifying therapies exist for PSP, representing a significant unmet medical need
Well-characterized biomarkers: CSF and PET tau biomarkers allow for early signal detectionStudy Design
The NCT04539041 study was designed as a Phase 1 single ascending dose study in PSP patients:
- Single ascending dose study: Multiple dose cohorts with increasing amounts of NIO752
- Intrathecal administration: Direct delivery into cerebrospinal fluid to bypass the blood-brain barrier[@johnson2022]
- Multiple dose cohorts: Sequential enrollment at different dose levels
- Safety and PK as primary endpoints: Evaluation of tolerability and pharmacokinetics
- Target engagement biomarkers: CSF tau measurement to confirm pharmacological activity
Preclinical studies in non-human primates have characterized the distribution of ASOs following intrathecal delivery, demonstrating broad coverage of brain regions relevant to neurodegenerative disease including subcortical structures affected in PSP[@depping2022].
Results and Outcomes
Safety and Tolerability
The Phase 1 study established that NIO752 was well-tolerated at all dose levels tested. The safety considerations included:
Common Adverse Events:
- Injection site reactions (common with intrathecal delivery)
- Headache (expected with lumbar puncture)
- Back pain
Monitoring Requirements:
- Regular neurological examinations
- CSF cell count and chemistry monitoring
- Platelet counts (ASOs can cause thrombocytopenia with systemic delivery, less common with intrathecal)
- Liver function tests
The safety profile observed in the PSP study aligns with experience from other CNS-targeting ASO programs, where intrathecal delivery has been used safely in multiple clinical trials.
Target Engagement
A critical finding from the study was the demonstration of target engagement through reduced cerebrospinal fluid tau levels[@aldn2024][@lane2023]. This represents a key validation that:
The ASO reached its target in the central nervous system
The mechanism of action (RNase H1-mediated mRNA degradation) functioned as designed
Tau production was reduced at the protein levelThis biomarker evidence establishes the pharmacological proof-of-concept for the tau reduction approach in human patients, supporting advancement to later-stage clinical trials.
Dose Selection for Future Studies
The Phase 1 data establish the dosing regimen for Phase 2 development. Key considerations include:
- Maximum tolerated dose: Identified through dose escalation
- Efficacy dose: Selection based on target engagement (CSF tau reduction)
- Therapeutic window: Balancing efficacy with safety based on preclinical models showing 50-60% tau reduction is well-tolerated[@schneider2022]
Significance and Implications
For PSP Treatment Development
NIO752 represents a disease-modifying approach that:
- Directly targets tau pathology: Addresses the underlying cause of neurodegeneration rather than symptoms
- Provides sustained effect: Unlike antibody approaches that require frequent dosing, ASO effects persist
- Could modify disease progression: By reducing tau burden early in the disease course
The successful completion of this Phase 1 study establishes the foundation for a broader tau reduction franchise. Following the PSP study, Roche advanced NIO752 into the TRAILRUNNER-ALZ Phase II clinical trial (NCT05519397) in Alzheimer's disease, evaluating the same ASO approach in the larger AD population.
Comparison to Other Tau-Targeting Approaches
Multiple tau-targeting therapeutic strategies have been pursued in clinical development:
| Approach | Examples | Status |
|----------|----------|--------|
| Active Immunization | ACI-35, LY3303560 | Various phases |
| Passive Immunization (N-terminal) | gosuranemab, tilavonemab | Failed |
| Passive Immunization (MTBR) | eilanetug, bepranemab | In development |
| Small Molecule Inhibitors | Kinase inhibitors, aggregation inhibitors | Preclinical/Phase 1 |
| Gene Silencing (ASO) | NIO752, BIIB080 | Phase 2 |
The failure of multiple N-terminal targeting antibodies has shifted emphasis toward MTBR-targeting antibodies and ASO approaches. The ASO strategy represents the most direct genetic intervention for tau reduction and may offer advantages in terms of target engagement depth and duration.
NIO752 in Alzheimer's Disease
Following the PSP Phase 1 study, NIO752 advanced into the TRAILRUNNER-ALZ Phase II clinical trial (NCT05519397) in early Alzheimer's disease. This study represents a critical test of whether tau reduction using an ASO approach can translate into clinical benefit for patients with AD.
Study Design:
- Population: Patients with early Alzheimer's disease (MCI due to AD or mild dementia)
- Design: Randomized, double-blind, placebo-controlled
- Route: Intrathecal administration
- Duration: Multi-dose regimen with extended follow-up
Primary Endpoints:
- Safety and tolerability
- Change in cerebrospinal fluid total tau
- Change in cognitive endpoints (ADAS-Cog13, CDR-SB)
BIIB080 (MAPTRx) Comparison
Biogen's BIIB080 (formerly IONIS-MAPTRx, now MAPTRx) is a similar ASO targeting MAPT mRNA that has advanced further in clinical development:
| Feature | NIO752 (Roche) | BIIB080 (Biogen) |
|---------|----------------|-------------------|
| Developer | Roche/Ionis | Biogen/Ionis |
| Phase | Phase 1 (PSP), Phase 2 (AD) | Phase 2 |
| Dose | Established from Phase 1 | 10-60 mg tested |
| CSF tau reduction | Demonstrated | 50-60% at highest dose |
| Administration | Intrathecal | Intrathecal |
Biomarker Strategy and Endpoints
Cerebrospinal Fluid Biomarkers
The clinical trials for NIO752 employ multiple biomarker endpoints to assess target engagement and therapeutic response. Cerebrospinal fluid (CSF) biomarkers serve as the primary pharmacodynamic readouts:
Primary CSF Biomarkers:
- CSF total tau: Direct measurement of tau protein in cerebrospinal fluid, serving as a direct marker of target engagement
- CSF phosphorylated tau: p-tau181 and p-tau217, which are more specific markers of tau pathology and neurodegeneration
The reduction in CSF tau levels observed in the NCT04539041 study demonstrates that NIO752 achieves meaningful target engagement in PSP patients[@aldn2024][@lane2023]. This biomarker effect is critical for dose selection and provides early evidence of pharmacological activity before clinical outcomes can be assessed.
Secondary CSF Biomarkers:
- Neurofilament light chain (NfL): Marker of neuroaxonal injury that may reflect disease progression
- YKL-40: Marker of neuroinflammation
- Total protein and cell counts: Safety monitoring
Imaging Biomarkers
While not the primary endpoints in Phase 1, tau PET imaging represents an important secondary endpoint in later-stage trials:
- [^18F]flortaucipir PET: Measures regional tau burden in the brain
- MRI volumetric measures: Brain volume changes as a marker of neurodegeneration
The biomarker strategy allows for dose optimization and early signal detection, even before clinical outcomes can be fully assessed in lengthy PSP trials[@lane2023].
Pharmacokinetics and Distribution
Intrathecal Delivery Rationale
NIO752 is administered via intrathecal injection, which delivers the ASO directly into the cerebrospinal fluid (CSF) space surrounding the spinal cord and brain[@johnson2022]. This route is necessary because systemically administered ASOs do not efficiently cross the blood-brain barrier.
Key aspects of intrathecal delivery include:
- Bypassing the blood-brain barrier: Direct CSF administration avoids the need for CNS uptake from the periphery
- Distribution: ASOs in CSF distribute throughout the central nervous system via CSF flow, reaching subcortical structures relevant to PSP
- Tissue penetration: ASOs enter brain tissue from the CSF, reaching neurons and other CNS cell types including those in the basal ganglia and brainstem
- Dosing frequency: The half-life of ASOs in CNS tissue supports monthly or less frequent dosing
Dose Rationale and Therapeutic Window
An important consideration for tau-targeting therapies is the therapeutic window between pathological tau reduction and disruption of normal tau function. Tau is not merely a pathological protein; it plays essential roles in neuronal health, including microtubule stabilization, axonal transport, and synaptic function.
Preclinical studies have established that partial tau reduction (50-60%) is well-tolerated and provides neuroprotection in mouse models. This aligns with the target engagement seen in the NIO752 program, where CSF tau reduction was achieved without concerning safety signals. The ASO approach allows for dose titration to achieve optimal tau reduction within this therapeutic window[@schneider2022].
Scientific Context and Rationale
The Tau Hypothesis in PSP
The tau hypothesis posits that tau protein aggregation and propagation drives neurotoxicity in PSP and related tauopathies[@smith2023]. This hypothesis is supported by multiple lines of evidence:
Neuropathological staging: The distribution of neurofibrillary tangles (NFTs) correlates with clinical phenotype in PSP, with specific patterns affecting the basal ganglia, brainstem, and cerebellar nuclei
Genetic evidence: Mutations in MAPT cause familial frontotemporal dementia with parkinsonism, demonstrating that tau dysregulation is sufficient to cause neurodegeneration
Biomarker correlations: CSF and PET tau markers correlate with disease severity and progression in PSP
Experimental models: Tau reduction in mouse models prevents neurodegeneration and improves motor functionGene Silencing vs. Antibody Clearance
The ASO approach to tau reduction differs fundamentally from antibody-based immunotherapies that have been tested in numerous clinical trials. Understanding this distinction is critical for appreciating NIO752's therapeutic rationale:
Antibody Approach:
- Target extracellular tau that has already been released from neurons
- Require antibodies to cross the blood-brain barrier (limited penetration)
- Clear tau after it has already accumulated
- Depend on peripheral mechanisms (antibody-Fc interactions) for clearance
ASO Approach:
- Target tau production at the source (mRNA in neurons)
- Delivered directly to CNS via intrathecal administration
- Prevent tau from being produced, addressing the root cause
- Reduce all tau species including intracellular tau that antibodies cannot access
The theoretical advantages of the ASO approach include more complete tau reduction, targeting of intracellular tau, and potentially greater disease-modifying potential by addressing the upstream cause of pathology[@tau2024][@schneider2022].
Safety Considerations
Observed Safety Profile
As an ASO delivered intrathecally, NIO752 has demonstrated an acceptable safety profile in clinical trials to date. The safety considerations include:
Common Adverse Events:
- Injection site reactions (common with intrathecal delivery)
- Headache (expected with lumbar puncture)
- Back pain
- Transient CSF pleocytosis (mild white blood cell increase)
Monitoring Requirements:
- Regular neurological examinations
- CSF cell count and chemistry monitoring
- Platelet counts (ASOs can cause thrombocytopenia with systemic delivery, less common with intrathecal)
- Liver function tests
Comparison to Similar ASO Programs
The safety profile of NIO752 can be informed by experience with other CNS-targeting ASOs in development, including BIIB080 and ASOs targeting other neurological disease genes. The intrathecal route has been used safely in multiple clinical programs, and the ASO chemistry has been refined over decades of development to minimize immunogenicity and off-target effects.
Long-term Safety Considerations
For a chronic neurodegenerative condition like PSP, long-term safety is paramount. Key considerations include:
- Sustained tau reduction: Long-term effects of tau reduction on normal brain function
- Immunogenicity: Potential for immune reactions to the ASO with repeated dosing
- Off-target effects: Minimizing effects on non-MAPT transcripts
- CSF dynamics: Effects of repeated lumbar punctures
Competitive Landscape
Tau-Targeting Therapeutic Strategies in PSP
The PSP therapeutic field has evolved significantly over the past decade. Multiple strategies have been pursued:
1. Active Immunization:
- Vaccines targeting tau (e.g., ACI-35)
- Goal: Generate antibodies that clear pathological tau
2. Passive Immunization (Monoclonal Antibodies):
- N-terminal targeting (gosuranemab, tilavonemab, zagotenemab)
- MTBR targeting (eilanetug, bepranemab)
3. Small Molecule Inhibitors:
- Kinase inhibitors to reduce tau phosphorylation
- Aggregation inhibitors
4. Gene Silencing (ASOs):
- NIO752 (Roche/Ionis) - Phase 1 completed
- BIIB080 (Biogen/Ionis) - Phase 2
The failure of multiple N-terminal targeting antibodies has shifted emphasis toward MTBR-targeting antibodies and ASO approaches. The ASO strategy represents the most direct genetic intervention for tau reduction and may offer advantages in terms of target engagement depth and duration.
Future Development Pathways
Success in the NIO752 PSP program could enable multiple development pathways:
Accelerated approval: Based on biomarker endpoints (CSF tau reduction)
Full approval: Based on clinical outcome data
Broader tauopathies: Potential expansion to CBD (corticobasal degeneration), FTD (frontotemporal dementia)
Combination therapy: Potential combination with other therapeutic approachesRoche has positioned NIO752 as part of a broader tau franchise alongside other tau-targeted therapies. The company's strategy suggests confidence in the ASO approach and a long-term commitment to developing tau-reduction therapies across multiple indications.
Future Directions
Unanswered Questions
Several questions remain to be answered in NIO752's development:
Optimal dosing: What is the optimal dose for efficacy while maintaining safety in PSP patients?
Clinical outcomes: Will tau reduction translate to clinical benefit in PSP?
Biomarker correlation: How do changes in CSF tau relate to tau PET and clinical measures in PSP?
Disease modification: Can early intervention alter disease trajectory in PSP?
Biomarker stratification: Are there biomarker subgroups that respond better to therapy?Broader Implications
Successful development of NIO752 would have significant implications for the field:
Validation of ASO platform: Demonstrating that gene silencing works for neurodegenerative disease
Tau hypothesis confirmation: Providing human evidence for the tau hypothesis in PSP
Precision medicine: Establishing biomarker-driven patient selection
Expansion to other tauopathies: Potential applicability beyond PSP to CBD, FTDThe development of NIO752 represents one of the most advanced tests of the tau reduction hypothesis in clinical settings. Whether through genetic, immunological, or small molecule approaches, reducing tau burden remains a compelling strategy for treating PSP and related disorders.
See Also
- [Tau Protein](/proteins/tau)
- [MAPT Gene](/genes/mapt)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Tau ASO Therapy](/mechanisms/tau-aso-therapy)
- [NIO752 Therapeutic Page](/therapeutics/nio752)
External Links
- [ClinicalTrials.gov - NCT04539041](https://clinicaltrials.gov/study/NCT04539041)
- [Roche Pipeline](https://www.roche.com/investors/pipelines)
- [Ionis Pharmaceuticals](https://www.ionispharma.com)
Related Pages
- [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
- [Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics)
- [PSP Pathway](/mechanisms/psp-pathway)
- [PSP Disease Page](/diseases/progressive-supranuclear-palsy)
References
[ClinicalTrials.gov - NCT04539041](https://clinicaltrials.gov/study/NCT04539041)
[BIIB080/MAPTRx ASO for Alzheimer's Disease](https://clinicaltrials.gov/study/NCT05339152)
[NIO752 first-in-human study: safety and pharmacokinetics (2024)](https://pubmed.ncbi.nlm.nih.gov/38982134/)
[Antisense oligonucleotides targeting tau: mechanisms of action and therapeutic potential (2021)](https://pubmed.ncbi.nlm.nih.gov/34536012/)
[Tauopathies: new perspectives from human studies (2023)](https://doi.org/10.1038/s41582-023-00789-9)
[RNase H1-mediated antisense mechanism for tau reduction (2023)](https://doi.org/10.1089/nat.2023.0123)
[CSF tau biomarkers in ASO clinical trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Tau reduction as a therapeutic strategy: evidence and considerations (2022)](https://pubmed.ncbi.nlm.nih.gov/35689045/)
[Intrathecal ASO delivery: overcoming the blood-brain barrier (2022)](https://doi.org/10.1038/s41573-022-00567-4)
[Intrathecal delivery of ASO in non-human primates (2022)](https://doi.org/10.1016/j.ymthe.2022.01.019)
[MAPT gene and tau biology review (2024)](https://doi.org/10.1038/s41582-024-00850-3)
[Tau ASO mechanisms in neurodegenerative disease (2024)](https://doi.org/10.1002/alz.13850)